{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:49:51Z","timestamp":1792039791852,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40264-026-01695-1","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T17:06:08Z","timestamp":1784394368000},"page":"1525-1533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ponatinib Safety Profile: An Analysis of 10 Years of Real-World Experience"],"prefix":"10.1007","volume":"49","author":[{"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Castagnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouna","family":"Bardey-Kanaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romuald","family":"Soichez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhan Thanh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Patos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valent\u00edn","family":"Garc\u00eda-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"key":"1695_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100825","volume":"49","author":"AEG Osman","year":"2021","unstructured":"Osman AEG, Deininger MW. Chronic myeloid leukemia: modern therapies, current challenges and future directions. Blood Rev. 2021;49:100825. https:\/\/doi.org\/10.1016\/j.blre.2021.100825.","journal-title":"Blood Rev"},{"key":"1695_CR2","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ajh.27443","volume":"99","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024;99:2191\u2013212. https:\/\/doi.org\/10.1002\/ajh.27443.","journal-title":"Am J Hematol"},{"key":"1695_CR3","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1001\/jamaoncol.2022.2398","volume":"8","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Haddad FG, Short NJ, Kantarjian H. Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-from intensive chemotherapy combinations to chemotherapy-free regimens: a review. JAMA Oncol. 2022;8:1340\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2022.2398.","journal-title":"JAMA Oncol"},{"key":"1695_CR4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O'Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16:401\u201312. https:\/\/doi.org\/10.1016\/j.ccr.2009.09.028.","journal-title":"Cancer Cell"},{"key":"1695_CR5","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1306494.","journal-title":"N Engl J Med"},{"key":"1695_CR6","unstructured":"US Food and Drug Administration. ICLUSIG\u00ae (ponatinib). Prescribing information. Takeda Pharmaceutical Company Limited. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/203469s038lbl.pdf. Accessed 27 Jan 2026."},{"key":"1695_CR7","unstructured":"European Medicines Agency. ICLUSIG\u00ae (ponatinib). Summary of product characteristics. Incyte Biosciences Distribution B.V. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/iclusig-epar-product-information_en.pdf. Accessed 27 Jan 2026."},{"key":"1695_CR8","unstructured":"European Medicines Agency. PRAC updates on the risks of serious vascular occlusive events associated with cancer medicine Iclusig. 2013. https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/prac-updates-risks-serious-vascular-occlusive-events-associated-cancer-medicine-iclusig_en.pdf. Accessed 20 Jan 2025."},{"key":"1695_CR9","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. Iclusig (Ponatinib) Tablets Risk Evaluation and Mitigation Strategy (REMS). ARIAD Pharmaceuticals, Inc. 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/203469Orig1s007,s008.pdf. Accessed 12 Aug 2025."},{"key":"1695_CR10","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1182\/blood.2021012082","volume":"138","author":"J Cortes","year":"2021","unstructured":"Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138:2042\u201350. https:\/\/doi.org\/10.1182\/blood.2021012082.","journal-title":"Blood"},{"key":"1695_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01221-z","volume":"15","author":"JL Januzzi","year":"2022","unstructured":"Januzzi JL, Garasic JM, Kasner SE, McDonald V, Petrie MC, Seltzer J, et al. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. J Hematol Oncol. 2022;15:1. https:\/\/doi.org\/10.1186\/s13045-021-01221-z.","journal-title":"J Hematol Oncol"},{"key":"1695_CR12","unstructured":"US Food and Drug Administration. ARIAD Pharmaceuticals, Inc. Iclusig (Ponatinib) Tablets Risk Evaluation and Mitigation Strategy (REMS). 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2018\/203469Orig1s029ltr.pdf. Accessed 20 Jan 2025."},{"key":"1695_CR13","unstructured":"European Medicines Agency. EU Risk Management Plan For Iclusig (Ponatinib) https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/iclusig-epar-risk-management-plan-summary_en.pdf. Accessed 20 Jan 2025."},{"key":"1695_CR14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393\u2013404. https:\/\/doi.org\/10.1182\/blood-2016-09-739086.","journal-title":"Blood"},{"key":"1695_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","volume":"48","author":"DJ Dorer","year":"2016","unstructured":"Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, et al. Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016;48:84\u201391. https:\/\/doi.org\/10.1016\/j.leukres.2016.07.007.","journal-title":"Leuk Res"},{"key":"1695_CR16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.e18052","volume":"33","author":"JE Cortes","year":"2015","unstructured":"Cortes JE, Kim DG, Pinilla-Ibarz J, Coutre PDL, Paquette R, Chuah C, et al. Efficacy and safety of ponatinib in heavily pretreated leukemia patients in the PACE trial: 3-year results. J Clin Oncol. 2015;33:e18052. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.e18052.","journal-title":"J Clin Oncol"},{"key":"1695_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome\u2013positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393\u2013404. https:\/\/doi.org\/10.1182\/blood-2016-09-739086.","journal-title":"Blood"},{"key":"1695_CR18","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood-2024-207634","volume":"144","author":"JE Cortes","year":"2024","unstructured":"Cortes JE, Deininger MW, Apperley J, Arthur CK, Chuah C, Hochhaus A, et al. 5-year follow-up of the phase 2 OPTIC study in patients with chronic-phase chronic myeloid leukemia: efficacy, safety, and first end-of-treatment mutational results. Blood. 2024;144:3148. https:\/\/doi.org\/10.1182\/blood-2024-207634.","journal-title":"Blood"},{"key":"1695_CR19","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1182\/blood-2023-178790","volume":"142","author":"J Cortes","year":"2023","unstructured":"Cortes J, Deininger M, Lomaia E, Moiraghi B, Undurraga S, Pavlovsky C, et al. Long-term results from the optic trial: a dose-optimization study of 3 starting doses of ponatinib. Blood. 2023;142:3164. https:\/\/doi.org\/10.1182\/blood-2023-178790.","journal-title":"Blood"},{"key":"1695_CR20","doi-asserted-by":"publisher","first-page":"S373","DOI":"10.1016\/S2152-2650(24)01317-X","volume":"24","author":"J Cortes","year":"2024","unstructured":"Cortes J, Deininger M, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, et al. CML-425 dose-optimization study of 3 starting doses of ponatinib: long-term results from the OPTIC trial. Clin Lymphoma Myeloma Leuk. 2024;24:S373. https:\/\/doi.org\/10.1016\/S2152-2650(24)01317-X.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1695_CR21","first-page":"1","volume-title":"Side-effects of anti-inflammatory drugs, advances in inflammation research","author":"JCP Weber","year":"1984","unstructured":"Weber JCP. Epidemiology of adverse reactions to nonsteroidal anti\u2010inflammatory drugs. In: Rainsford KD, Velo GD, editors. Side-effects of anti-inflammatory drugs, advances in inflammation research. New York: Raven Press; 1984. p. 1\u20137."},{"key":"1695_CR22","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1592\/phco.24.8.743.36068","volume":"24","author":"NR Hartnell","year":"2004","unstructured":"Hartnell NR, Wilson JP. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food And Drug Administration. Pharmacotherapy J Hum Pharmacol Drug Therapy: 2004;24:743\u20139. https:\/\/doi.org\/10.1592\/phco.24.8.743.36068.","journal-title":"Pharmacotherapy J Hum Pharmacol Drug Therapy."},{"key":"1695_CR23","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2147\/tcrm.S137144","volume":"13","author":"A Arora","year":"2017","unstructured":"Arora A, Jalali RK, Vohora D. Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs. Ther Clin Risk Manag. 2017;13:1195\u2013203. https:\/\/doi.org\/10.2147\/tcrm.S137144.","journal-title":"Ther Clin Risk Manag"},{"key":"1695_CR24","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s40264-013-0115-x","volume":"36","author":"P Chhabra","year":"2013","unstructured":"Chhabra P, Chen X, Weiss SR. Adverse event reporting patterns of newly approved drugs in the USA in 2006: an analysis of FDA adverse event reporting system data. Drug Saf. 2013;36:1117\u201323. https:\/\/doi.org\/10.1007\/s40264-013-0115-x.","journal-title":"Drug Saf"},{"key":"1695_CR25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","volume":"37","author":"KB Hoffman","year":"2006","unstructured":"Hoffman KB, Dimbil M, Erdman CB, Tatonetti NP, Overstreet BM. The Weber effect and the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 2006;37:283\u201394. https:\/\/doi.org\/10.1007\/s40264-014-0150-2.","journal-title":"Drug Saf"},{"key":"1695_CR26","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","volume":"30","author":"A Pariente","year":"2007","unstructured":"Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30:891\u20138. https:\/\/doi.org\/10.2165\/00002018-200730100-00007.","journal-title":"Drug Saf"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01695-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01695-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01695-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:42:06Z","timestamp":1792039326000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01695-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1695"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01695-1","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EJ reports consulting or having an advisory role for AbbVie, Adaptive Biotechnologies, Amgen, Astellas Pharma, Bristol Myers Squibb, Genentech, Incyte, Pfizer, and Takeda; and receiving research funding from AbbVie, Adaptive Biotechnologies, Amgen, Ascentage Pharma Group, Pfizer, and Takeda. FC reports receiving honoraria for advisory boards\/consultancies\/speakers\u2019 bureaus from BMS\/Celgene, Incyte, Novartis, Pfizer, and Zentiva; and receiving institutional research support from BMS\/Celgene, Incyte, Novartis, and Pfizer. MB-K, RS, NTN, DK, FR, and PP report employment and stock ownership with Incyte Corporation. VG-G reports research funding from Bristol Myers Squibb, GlaxoSmithKline, Incyte, Novartis, and Pfizer; receiving honoraria from Bristol Myers Squibb, CTA, GlaxoSmithKline, Incyte, Novartis, and Pfizer; and providing expert testimony for Bristol Myers Squibb, GlaxoSmithKline, Incyte, Novartis, and Pfizer.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Incyte Corporation (Wilmington, DE) is committed to data sharing that advances science and medicine while protecting patient privacy. Qualified external scientific researchers may request anonymized data sets owned by Incyte for the purpose of conducting legitimate scientific research. Researchers may request anonymized data sets from any interventional study (except phase 1 studies) for which the product and indication have been approved on, or after, 1 January 2020 in at least one major market (e.g., USA, EU, and Japan). Data will be available for request after the primary publication, or 2 years after the study has ended. Information on Incyte\u2019s clinical trial data sharing policy and instructions for submitting clinical trial data requests are available at:\n                      \n                      .","order":2,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EJ, FC, MB-K, RS, NTN, and VG-G conceptualized the study; MB-K was responsible for resources; RS and NTN curated the data; RS and NTN performed the formal analysis; MB-K and DK supervised; RS and NTN were responsible for validation; RS and NTN performed the investigation; RS and NTN were responsible for visualization; MB-K, RS, and NTN were responsible for the methodology; EJ, MB-K, RS, and NTN wrote the original draft; MB-K was responsible for project administration; EJ, FC, MB-K, RS, NTN, DK, FR, and VG-G reviewed and edited the manuscript. All authors read and approved the final version of the manuscript.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}